Detail

Vandetanib

Description

Name: Vandetanib
Type: small molecule
Groups: approved
Indication: Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.
Accession Number: DB05294 ( DB05294)
Description: Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.
Structure:
Prescription Products:
NameDosageStrengthRouteMarketing StartMarketing EndCountry
Caprelsatablet100 mgoral23-02-2012Canada
Caprelsatablet300 mgoral23-02-2012Canada
Caprelsatablet100 mg/1oral25-07-2011US
Caprelsatablet300 mg/1oral25-07-2011US
Vandetanibtablet100 mg/1oral21-04-2011US
Vandetanibtablet300 mg/1oral21-04-2011US

Generic Prescription Products: Not Available
Over the Counter Products: Not Available
International Brands
  • No Brands

Brand Names
  • No Brands

Brand Mixtures
Brand NameIngredients
VandetanibVandetanib
CaprelsaVandetanib
VandetanibVandetanib
CaprelsaVandetanib
CaprelsaVandetanib
CaprelsaVandetanib

Categories
  • No Category

Pharmacology

Indication: Vandetanib is currently approved as an alternative to local therapies for both unresectable and disseminated disease. Because Vandetanib can prolong the Q-T interval, it is contraindicated for use in patients with serious cardiac complications such as congenital long QT syndrome and uncompensated heart failure.
Pharmacodynamics: Not Available
Mechanism of action: ZD-6474 is a potent and selective inhibitor of VEGFR (vascular endothelial growth factor receptor), EGFR (epidermal growth factor receptor) and RET (REarranged during Transfection) tyrosine kinases. VEGFR- and EGFR-dependent signalling are both clinically validated pathways in cancer, including non-small-cell lung cancer (NSCLC). RET activity is important in some types of thyroid cancer, and early data with vandetanib in medullary thyroid cancer has led to orphan-drug designation by the regulatory authorities in the USA and EU.
Absorption: Slow- peak plasma concentrations reached at a median 6 hours. On multiple dosing, Vandetanib accumulates about 8 fold with steady state reached after around 3 months.
Volume of distribution:
    Vd of about 7450 L.

Protein binding: Protein binding of about 90%.
Metabolism: Not Available
Route of elimination: About 69% was recovered following 21 days after a single dose of vandentanib. 44% was found in feces and 25% in urine.
Half life: Median half life of 19 days.
Clearance: Not Available
Toxicity: Not Available
Affected organisms
  • Not Available

SNP Mediated Adverse Drug Reactions
  • Not Available

Pharmacoeconomics

Manufacturers:
  • Not Available

Packagers:
  • Not Available

Dosage forms
FormRouteStrength
Tabletoral100 mg
Tabletoral300 mg
Tabletoral100 mg/1
Tabletoral300 mg/1

Prices
Unit descriptionCostUnit

Patents
CountryPatent NumberApprovedExpires (estimated)
7173038United States2007-02-062021-08-14
8067427United States2011-11-292028-08-08

Interactions

Drug Interactions
DrugInteraction
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Vandetanib.
BexaroteneThe serum concentration of Vandetanib can be decreased when it is combined with Bexarotene.
BosentanThe serum concentration of Vandetanib can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Vandetanib.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Vandetanib.
CarbamazepineThe serum concentration of Vandetanib can be decreased when it is combined with Carbamazepine.
CitalopramCitalopram may increase the QTc-prolonging activities of Vandetanib.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Vandetanib.
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Vandetanib.
DabrafenibThe serum concentration of Vandetanib can be decreased when it is combined with Dabrafenib.
DeferasiroxThe serum concentration of Vandetanib can be decreased when it is combined with Deferasirox.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Vandetanib.
DofetilideDofetilide may increase the QTc-prolonging activities of Vandetanib.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Vandetanib.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Vandetanib.
EnzalutamideThe serum concentration of Vandetanib can be decreased when it is combined with Enzalutamide.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Vandetanib.
FosphenytoinThe serum concentration of Vandetanib can be decreased when it is combined with Fosphenytoin.
GoserelinGoserelin may increase the QTc-prolonging activities of Vandetanib.
IvabradineIvabradine may increase the QTc-prolonging activities of Vandetanib.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Vandetanib.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Vandetanib.
MetforminThe serum concentration of Metformin can be increased when it is combined with Vandetanib.
MifepristoneMifepristone may increase the QTc-prolonging activities of Vandetanib.
MitotaneThe serum concentration of Vandetanib can be decreased when it is combined with Mitotane.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Vandetanib.
OctreotideOctreotide may increase the QTc-prolonging activities of Vandetanib.
PamidronateThe risk or severity of adverse effects can be increased when Vandetanib is combined with Pamidronate.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Vandetanib.
PhenobarbitalThe serum concentration of Vandetanib can be decreased when it is combined with Phenobarbital.
PhenytoinThe serum concentration of Vandetanib can be decreased when it is combined with Phenytoin.
PrimidoneThe serum concentration of Vandetanib can be decreased when it is combined with Primidone.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Vandetanib.
RifabutinThe serum concentration of Vandetanib can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Vandetanib can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Vandetanib can be decreased when it is combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Vandetanib.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Vandetanib.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Vandetanib.
SiltuximabThe serum concentration of Vandetanib can be decreased when it is combined with Siltuximab.
St. John's WortThe serum concentration of Vandetanib can be decreased when it is combined with St. John's Wort.
TocilizumabThe serum concentration of Vandetanib can be decreased when it is combined with Tocilizumab.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Vandetanib.
VerapamilThe serum concentration of Verapamil can be increased when it is combined with Vandetanib.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Vandetanib.

Food Interactions:
  • Not Available

Taxonomy

Kingdom: Organic compounds
Super Class: Not Available
Class: Not Available
Sub Class: Not Available
Direct Parent: Not Available
Alternative Parents:
  • Alkyl aryl ethers
  • Aminopyrimidines and derivatives
  • Anisoles
  • Aryl bromides
  • Aryl fluorides
  • Azacyclic compounds
  • Bromobenzenes
  • Fluorobenzenes
  • Heteroaromatic compounds
  • Hydrocarbon derivatives
  • Imidolactams
  • Organobromides
  • Organofluorides
  • Piperidines
  • Secondary amines
  • Trialkylamines

substituent:
  • Alkyl aryl ether
  • Amine
  • Aminopyrimidine
  • Anisole
  • Aromatic heteropolycyclic compound
  • Aryl bromide
  • Aryl fluoride
  • Aryl halide
  • Azacycle
  • Benzenoid
  • Bromobenzene
  • Ether
  • Fluorobenzene
  • Halobenzene
  • Heteroaromatic compound
  • Hydrocarbon derivative
  • Imidolactam
  • Monocyclic benzene moiety
  • Organobromide
  • Organofluoride
  • Organohalogen compound
  • Organonitrogen compound
  • Organooxygen compound
  • Piperidine
  • Pyrimidine
  • Quinazolinamine
  • Secondary amine
  • Tertiary aliphatic amine
  • Tertiary amine

References

Synthesis Reference: Not Available
General Reference: # Bates D: ZD-6474. AstraZeneca. Curr Opin Investig Drugs. 2003 Dec;4(12):1468-72. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/14763134 # Ton GN, Banaszynski ME, Kolesar JM: Vandetanib: A novel targeted therapy for the treatment of metastatic or locally advanced medullary thyroid cancer. Am J Health Syst Pharm. 2013 May 15;70(10):849-55. doi: 10.2146/ajhp120253. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/23640345 # Andriamanana I, Gana I, Duretz B, Hulin A: Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS. J Chromatogr B Analyt Technol Biomed Life Sci. 2013 May 1;926:83-91. doi: 10.1016/j.jchromb.2013.01.037. Epub 2013 Mar 16. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/23562906
External Links:
ResourceLink

ATC Codes:
  • Array

AHFS Codes:
  • Not Available

MSDS: Download
SiteLock

© Copyright 2022 The Purple Society, Purple Gladiator, Trialsmap, The Purple Drug Guide, and One Person CAN Make A Difference! are all registered trademarks of The Purple Society. The Purple Society, a not-for-profit, section 501(c)(3) #273785281.

The Purple Society website is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through this site should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, you should consult your health care provider.

CONTACT US

The Purple Society team is here for you 24 hours a day, 7 days a week. Send us an email and we'll get right back to you.

Sending
or

Log in with your credentials

Forgot your details?